Olmesartan/Hidroclorotiazida Mabo (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Hidroclorotiazida Mabo, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with a diuretic, and is prescribed for adult patients. GNH USA supplies Olmesartan/Hidroclorotiazida Mabo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan/Hidroclorotiazida Mabo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Hidroclorotiazida Mabo is used within the renin‑angiotensin‑aldosterone system pathway to manage high blood pressure. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Heart failure adjunct: assists in fluid management when combined with diuretics. - Diabetic nephropathy protection: helps slow progression of kidney damage associated with diabetes. - Stroke prevention: contributes to long‑term risk reduction in patients with elevated blood pressure. - Post‑myocardial infarction care: supports blood‑pressure control as part of secondary prevention. - Resistant hypertension: provides an additional mechanism when standard therapy is insufficient.

Common Side Effects: - Dizziness or light‑headedness, especially after the first doses. - Headache. - Fatigue or mild weakness. - Increased urination. - Electrolyte disturbances such as low potassium. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Acute kidney injury or significant rise in serum creatinine. - Hyperkalemia or severe electrolyte imbalance. - Angio‑edema involving the face, lips or airway. - Hepatic dysfunction with jaundice. - Blood dyscrasias such as agranulocytosis or thrombocytopenia.

Before initiating therapy, consider the following precautions: - Renal function: assess baseline creatinine and eGFR, adjust if impaired. - Electrolytes: monitor potassium and sodium levels regularly. - Hepatic disease: use cautiously in patients with liver impairment. - Pregnancy: avoid use during the second and third trimesters; discuss risks with a physician. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Olmesartan/Hidroclorotiazida Mabo may interact with several medicines. Review the following categories:

Major Interactions (Avoid): - Aliskiren: concurrent use in diabetic patients can increase risk of renal dysfunction and hyperkalemia. - Potassium‑saving diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: additive risk of hypotension, hyperkalemia, and renal impairment. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.